|
EQS-News: PAION AG / Key word(s): Insolvency PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS – PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED 31.10.2023 / 15:16 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS – PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED Aachen (Germany), 31 October 2023 – The specialty pharma company PAION AG (ISIN DE000A3E5EG5; Frankfurt Stock Exchange, Prime Standard: PA8) announces that, in accordance with the ad hoc announcement dated October 26, 2023, it filed for the opening of insolvency proceedings with the Local Court of Aachen, Insolvency Court, on Friday, October 27, 2023. Furthermore, an insolvency petition was also filed by PAION AG’s subsidiary PAION Deutschland GmbH. Attorney Dr. Mark Boddenberg has been appointed as the preliminary insolvency administrator of PAION AG and PAION Deutschland GmbH.
Contact Ralf Penner SVP Investor Relations & Corporate Communications PAION AG Heussstrasse 25 52078 Aachen – Germany Phone +49 241 4453-152 E-mail r.penner@paion.com www.paion.com 31.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal
January 5, 2024